@article{81680ddb0e6d42659952cd43b8aa3f8f,
title = "Forecasting cytokine storms with new predictive biomarkers",
abstract = "T cells genetically modified with CD19 chimeric antigen receptors have produced impressive clinical responses in patients with refractory B-cell malignancies, but therapeutic responses are often accompanied by cytokine release syndrome (CRS), which can cause significant morbidity and mortality. Teachey and colleagues have identified predictive biomarkers for this complication that may allow testing of earlier intervention with agents such as the IL6 receptor blocker tocilizumab to evaluate whether CRS can be ameliorated without jeopardizing clinical responses.",
author = "Rouce, {Rayne H.} and Helen Heslop",
note = "Funding Information: R.H. Rouce has received speakers bureau honoraria from the Novartis Treatment Advisory Board Landscape Meeting and is a consultant advisory board member for the same. H.E. Heslop reports receiving commercial research support from Celgene and has ownership interest (including patents) in ViraCyte and patents with Cell Medica. Grant Support The authors are supported by Lymphoma Research Foundation grant 337548 (R.H. Rouce), the American Society of Hematology Harold Amos Foundation (R.H. Rouce), NCI SPORE P50 CA126752 (H.E. Heslop), NCI:PPG PO1CA094237 (H.E. Heslop), Leukemia and Lymphoma Society SCOR 7018-04 (H.E. Heslop), and CPRIT RP110553-C1 (H.E. Heslop). Publisher Copyright: {\textcopyright} 2016 American Association for Cancer Research.",
year = "2016",
month = jun,
doi = "10.1158/2159-8290.CD-16-0493",
language = "English (US)",
volume = "6",
pages = "579--580",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "6",
}